Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.
Raig ND et al.
Science Advances, 2025
Aberrant ERK signaling in astrocytes impairs learning and memory in RASopathy-associated BRAF mutant mouse models.
Kang M et al.
The Journal of Clinical Investigation, 2025
Characterization of MEK1/2 Degraders Uncovers a Kinase-Independent Role for MEK1/2 in the Stabilization and Maturation of CRAF.
Wasserman JS et al.
Biorxiv : the Preprint Server for Biology, 2025
Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
Ham JM et al.
International Journal of Molecular Sciences, 2024
A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization.
Yu A et al.
The Journal of Biological Chemistry, 2023
ERK2 Mutations Affect Interactions, Localization, and Dimerization.
Taylor CA et al.
Biochemistry, 2023
Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function.
Fernandes LM et al.
Frontiers in Cell and Developmental Biology, 2023
Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Kubota Y et al.
Nature Communications, 2022
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
Cope NJ et al.
The Journal of Biological Chemistry, 2020
Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.
Kanavy DM et al.
Genome Medicine, 2019
Biochemical Characterization of Full-Length Oncogenic BRAFV600E together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases.
Cope N et al.
Chembiochem : a European Journal of Chemical Biology, 2019
Analysis of the Human Kinome and Phosphatome by Mass Cytometry Reveals Overexpression-Induced Effects on Cancer-Related Signaling.
Lun XK et al.
Molecular Cell, 2019
Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.
Verlande A et al.
Embo Reports, 2018
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM et al.
Molecular Cancer Research : Mcr, 2017
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Kang HB et al.
Molecular Cell, 2015
MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR.
Zhang L et al.
Neuron, 2014
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.
Martini M et al.
Cancer Research, 2013
Phosphorylation of mRNA decapping protein Dcp1a by the ERK signaling pathway during early differentiation of 3T3-L1 preadipocytes.
Chiang PY et al.
Plos One, 2013
A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program.
Choi MC et al.
Molecular Cell, 2012
Oncogenic MAP2K1 mutations in human epithelial tumors.
Choi YL et al.
Carcinogenesis, 2012
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.
Anastasaki C et al.
Human Molecular Genetics, 2009
Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T et al.
Human Molecular Genetics, 2008
Differential regulation of interleukin 5-stimulated signaling pathways by dynamin.
Gorska MM et al.
The Journal of Biological Chemistry, 2006
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P et al.
Science (new York, N.y.), 2006
Overexpression of MyoD-inducible lysosomal sialidase (neu1) inhibits myogenesis in C2C12 cells.
Champigny MJ et al.
Experimental Cell Research, 2005
Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2.
Arnaud M et al.
The Biochemical Journal, 2004
Translational control by MAPK signaling in long-term synaptic plasticity and memory.
Kelleher RJ et al.
Cell, 2004
Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Brognard J et al.
Cell Death and Differentiation, 2002
Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.
Robinson FL et al.
The Journal of Biological Chemistry, 2002
The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation.
Grammatikakis N et al.
The Journal of Biological Chemistry, 2002
Critical contribution of linker proteins to Raf kinase activation.
Anselmo AN et al.
The Journal of Biological Chemistry, 2002
A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3.
Li Z et al.
The Journal of Biological Chemistry, 2001
Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking.
Xu Be et al.
The Journal of Biological Chemistry, 2001
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.
Wang C et al.
The Journal of Biological Chemistry, 2001
Kinase suppressor of Ras signals through Thr269 of c-Raf-1.
Xing HR et al.
The Journal of Biological Chemistry, 2001
Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression. Requirement for phosphorylation at the activation lip and signaling downstream of MKK.
Tolwinski NS et al.
The Journal of Biological Chemistry, 1999
Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades.
Gum R et al.
Oncogene, 1997
Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.
Lengyel E et al.
The Journal of Biological Chemistry, 1995
Active erk regulates microtubule stability in H-ras-transformed cells.
Harrison RE et al.
Neoplasia (new York, N.y.), 0
TLR-4 agonistic lipopolysaccharide upregulates interleukin-8 at the transcriptional and post-translational level in vascular smooth muscle cells.
Hong TJ et al.
Vascular Pharmacology, 0